Philip L. Mar
Research Subjects
Philip L. Mar has a total of 148 co-authors. Here are the top co-authors by number of shared publications:
- Rakesh Gopinathannair
Kansas City Heart Rhythm Institute, Overland Park, KS, USA
10 shared publications - Satish R. Raj
Department of Cardiac Sciences, Libin Cardiovascular Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
8 shared publications - Dhanunjaya Lakkireddy
Kansas City Heart Rhythm Institute, Overland Park, USA
7 shared publications Christina Tsai
Division of Cardiology, St. Louis University, St. Louis, USA
5 shared publicationsYixi Tu
Saint Louis University Hospital, Department of Medicine, MO; Saint Louis University Hospital, Division of Gastroenterology, MO
5 shared publicationsAmmar Nasir
Saint Louis University, Saint Louis, MO, USA
4 shared publications
Latest Publications
- 28 August 2024
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 10 (10) , 2297-2299
First in Human
- 28 August 2024
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 10 (10) , 2297-2299
First in Human
- 26 October 2023
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 67 (5) , 1127-1132
Poorer outcomes associated with more invasive lead management strategies for Abbott Riata® leads: a large, multicenter experience
Background Over 100,000 Abbott Riata® were implanted in the United States before they were recalled in 2010. There are still a significant number of Abbott Riata® leads in use, and it is unclear how these leads should be managed at the time of generator change or lead malfunction. Although data comparing both Sprint Fidelis® and Abbott Riata® leads in this setting is available, there are no multicenter comparative studies of outcomes for various lead management strategies, including lead extraction (LE), lead abandonment/revision (LA), and generator change (GC) only at the time of device at elective replacement interval (ERI) for Abbott Riata® leads. Methods A retrospective, multicenter study was undertaken to compare short-term outcomes (major complications—MC, death, extended or re-hospitalizations within 60 days—RH, lead malfunction—LM) and total outcomes (short-term outcomes & lead malfunction during follow-up) of patients with Riata® leads undergoing LE, LA, or GC. Results 152 patients (65 ± 13 years, 68% male) were followed for a mean 33 ± 30 months following intervention. Out of 166 procedures, 13 patients underwent LE, 16 patients underwent LA, and 137 patients underwent GC. There was 1 major complication in each group, yielding an event rate of 7.7% for LE, 6.3% for LA, and 0.7% for GC cohorts. There were significantly more short-term and total adverse outcomes in the group of patients getting LE and LA versus GC only (38.5% & 31.3% vs 7.3%, P < 0.001). Total Riata® lead dwell time follow-up was 17,067 months. A total of 3 Riata® lead malfunctions were noted during long-term follow-up. Inappropriate shocks were similar between LE 7.7% (1/13), LA 6.3% (1/16). and GC 11.0% (4/136); P = 0.57. Conclusions There were more short-term and total adverse outcomes in more invasive management strategies (LE and LA) versus GC alone. The failure rate of Riata® leads was substantially lower compared to previous reports. Therefore, we recommend only performing battery exchange when a device with an active Riata® lead is at ERI, unless there is malfunction of the Riata® lead noted on testing. Graphical abstract There were significantly more short-term adverse outcomes in the lead extraction (5/13) and lead abandonment/revision (5/16) groups than the generator only (8/137) group (P < 0.001). GIB – Gastrointestinal bleed, CHF – congestive heart failure, NSTEMI – non-ST elevation MI
- 26 October 2023
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 67 (5) , 1127-1132
Poorer outcomes associated with more invasive lead management strategies for Abbott Riata® leads: a large, multicenter experience
Background Over 100,000 Abbott Riata® were implanted in the United States before they were recalled in 2010. There are still a significant number of Abbott Riata® leads in use, and it is unclear how these leads should be managed at the time of generator change or lead malfunction. Although data comparing both Sprint Fidelis® and Abbott Riata® leads in this setting is available, there are no multicenter comparative studies of outcomes for various lead management strategies, including lead extraction (LE), lead abandonment/revision (LA), and generator change (GC) only at the time of device at elective replacement interval (ERI) for Abbott Riata® leads. Methods A retrospective, multicenter study was undertaken to compare short-term outcomes (major complications—MC, death, extended or re-hospitalizations within 60 days—RH, lead malfunction—LM) and total outcomes (short-term outcomes & lead malfunction during follow-up) of patients with Riata® leads undergoing LE, LA, or GC. Results 152 patients (65 ± 13 years, 68% male) were followed for a mean 33 ± 30 months following intervention. Out of 166 procedures, 13 patients underwent LE, 16 patients underwent LA, and 137 patients underwent GC. There was 1 major complication in each group, yielding an event rate of 7.7% for LE, 6.3% for LA, and 0.7% for GC cohorts. There were significantly more short-term and total adverse outcomes in the group of patients getting LE and LA versus GC only (38.5% & 31.3% vs 7.3%, P < 0.001). Total Riata® lead dwell time follow-up was 17,067 months. A total of 3 Riata® lead malfunctions were noted during long-term follow-up. Inappropriate shocks were similar between LE 7.7% (1/13), LA 6.3% (1/16). and GC 11.0% (4/136); P = 0.57. Conclusions There were more short-term and total adverse outcomes in more invasive management strategies (LE and LA) versus GC alone. The failure rate of Riata® leads was substantially lower compared to previous reports. Therefore, we recommend only performing battery exchange when a device with an active Riata® lead is at ERI, unless there is malfunction of the Riata® lead noted on testing. Graphical abstract There were significantly more short-term adverse outcomes in the lead extraction (5/13) and lead abandonment/revision (5/16) groups than the generator only (8/137) group (P < 0.001). GIB – Gastrointestinal bleed, CHF – congestive heart failure, NSTEMI – non-ST elevation MI
- Open Access
- 25 August 2023
- Published by Radcliffe Medical Media Ltd in Arrhythmia and Electrophysiology Review
- Vol. 12, e24
Radiation-associated Arrhythmias: Putative Pathophysiological Mechanisms, Prevalence, Screening and Management Strategies
Radiation-associated cardiovascular disease, an increasingly recognised disease process, is a significant adverse effect of radiation therapy for common malignancies that involve the chest, and include lymphomas, lung, mediastinal and breast cancers. Two factors contribute to the increasing incidence of radiation-associated cardiovascular disease: advances in malignancy detection and the improved survival of cancer patients, by which many symptoms of radiation-associated cardiovascular disease, specifically radiation-associated arrhythmias, present years and/or decades following initial radiotherapy. We present a focused overview of the currently understood pathophysiology, prevalence and management strategies of radiation-associated arrhythmias, which include bradyarrhythmias, tachyarrhythmias and autonomic dysfunction.
- 25 August 2023
- Published by Radcliffe Medical Media Ltd in Arrhythmia and Electrophysiology Review
- Vol. 12, e24
Open AccessRadiation-associated Arrhythmias: Putative Pathophysiological Mechanisms, Prevalence, Screening and Management Strategies
Radiation-associated cardiovascular disease, an increasingly recognised disease process, is a significant adverse effect of radiation therapy for common malignancies that involve the chest, and include lymphomas, lung, mediastinal and breast cancers. Two factors contribute to the increasing incidence of radiation-associated cardiovascular disease: advances in malignancy detection and the improved survival of cancer patients, by which many symptoms of radiation-associated cardiovascular disease, specifically radiation-associated arrhythmias, present years and/or decades following initial radiotherapy. We present a focused overview of the currently understood pathophysiology, prevalence and management strategies of radiation-associated arrhythmias, which include bradyarrhythmias, tachyarrhythmias and autonomic dysfunction.
- 11 August 2023
- Published by Elsevier in International Journal of Cardiology
- Vol. 391, 131257
Comparison of quantifiable electrocardiographic changes associated with severe hyperkalemia
- 11 August 2023
- Published by Elsevier in International Journal of Cardiology
- Vol. 391, 131257
Comparison of quantifiable electrocardiographic changes associated with severe hyperkalemia
- 10 July 2023
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 46 (9) , 1099-1108
Electrophysiological evaluation following development of new and persistent left bundle branch block after transcatheter aortic valve replacement: A single center pilot study
Introduction: New and persistent left bundle branch block (NP‐LBBB) following Transcatheter Aortic Valve Replacement (TAVR) is an ongoing concern with incidence ranging from as low as 4% to up to 65% (varying for different types of valves). Such patients are at risk of developing high‐grade atrioventricular block (HAVB) warranting permanent pacemaker (PPM) implantation. However, currently, there are no consensus guidelines or large prospective studies to risk stratify these patients for safer discharge after TAVR.Objectives: To provide insight from a single center study on using modified electrophysiology (EP) study to risk stratify post‐TAVR patients to outpatient monitoring for low‐risk versus pacemaker implantation for high‐risk patients.Methods and Results: Between June 2020 and March 2023, all patients who underwent a TAVR procedure (324 patients) at our institution were screened for development of NP‐LBBB post‐operatively. Out of 26 patients who developed NP‐LBBB, after a pre‐specified period of observation, 18 patients were deemed eligible for a modified EP study to assess His‐Ventricular (HV) interval. 11 out of 18 patients (61.1%) had normal HV interval (HV < 55 ms). Three out of 18 patients (16.7%) had HV prolongation (55 ms < HV < 70 ms) without significant HV prolongation (defined as an increase in HV interval > 30%) with intra‐procedural procainamide challenge. Four out of 18 patients (22.2%) had significant HV prolongation (HV > 70 ms) warranting PPM implantation based on a multidisciplinary approach and shared decision‐making with the patients. Total of 50% of patients discharged with PPM (two out of four patients) were noted to be pacemaker dependent based on serial device interrogations. All patients who did not receive PPM were discharged with ambulatory monitoring with 30‐day event monitor and did not develop HAVB on serial follow‐up.Conclusion: Normal HV interval up to 55 ms on modified EP study after TAVR and development of NP‐LBBB can be utilized as a threshold for risk stratification to facilitate safe discharge. The optimal upper limit of HV interval threshold remains unclear in determining appropriate candidacy for PPM.
- 10 July 2023
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 46 (9) , 1099-1108
Electrophysiological evaluation following development of new and persistent left bundle branch block after transcatheter aortic valve replacement: A single center pilot study
Introduction: New and persistent left bundle branch block (NP‐LBBB) following Transcatheter Aortic Valve Replacement (TAVR) is an ongoing concern with incidence ranging from as low as 4% to up to 65% (varying for different types of valves). Such patients are at risk of developing high‐grade atrioventricular block (HAVB) warranting permanent pacemaker (PPM) implantation. However, currently, there are no consensus guidelines or large prospective studies to risk stratify these patients for safer discharge after TAVR.Objectives: To provide insight from a single center study on using modified electrophysiology (EP) study to risk stratify post‐TAVR patients to outpatient monitoring for low‐risk versus pacemaker implantation for high‐risk patients.Methods and Results: Between June 2020 and March 2023, all patients who underwent a TAVR procedure (324 patients) at our institution were screened for development of NP‐LBBB post‐operatively. Out of 26 patients who developed NP‐LBBB, after a pre‐specified period of observation, 18 patients were deemed eligible for a modified EP study to assess His‐Ventricular (HV) interval. 11 out of 18 patients (61.1%) had normal HV interval (HV < 55 ms). Three out of 18 patients (16.7%) had HV prolongation (55 ms < HV < 70 ms) without significant HV prolongation (defined as an increase in HV interval > 30%) with intra‐procedural procainamide challenge. Four out of 18 patients (22.2%) had significant HV prolongation (HV > 70 ms) warranting PPM implantation based on a multidisciplinary approach and shared decision‐making with the patients. Total of 50% of patients discharged with PPM (two out of four patients) were noted to be pacemaker dependent based on serial device interrogations. All patients who did not receive PPM were discharged with ambulatory monitoring with 30‐day event monitor and did not develop HAVB on serial follow‐up.Conclusion: Normal HV interval up to 55 ms on modified EP study after TAVR and development of NP‐LBBB can be utilized as a threshold for risk stratification to facilitate safe discharge. The optimal upper limit of HV interval threshold remains unclear in determining appropriate candidacy for PPM.
- 26 September 2022
- Published by Elsevier in The American Journal of Medicine
- Vol. 136 (2) , e20-e21
An Unusual Case of Diaphragmatic Stimulation Following Single Chamber ICD Implantation
- 26 September 2022
- Published by Elsevier in The American Journal of Medicine
- Vol. 136 (2) , e20-e21
An Unusual Case of Diaphragmatic Stimulation Following Single Chamber ICD Implantation
- 26 August 2022
- Published by Elsevier in The American Journal of Medicine
- Vol. 135 (9) , e377-E377
The Reply
- 26 August 2022
- Published by Elsevier in The American Journal of Medicine
- Vol. 135 (9) , e377-E377
The Reply
- 18 July 2022
- Published by Springer Nature in Current Cardiovascular Risk Reports
- Vol. 16 (11) , 121-129
Arrhythmia-Induced Cardiomyopathy: Mechanisms and Risk Assessment to Guide Management and Follow-Up
- 18 July 2022
- Published by Springer Nature in Current Cardiovascular Risk Reports
- Vol. 16 (11) , 121-129
Arrhythmia-Induced Cardiomyopathy: Mechanisms and Risk Assessment to Guide Management and Follow-Up